Jan 29 (Reuters) - Theravance Biopharma Inc:
* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
* THERAVANCE BIOPHARMA INC - FDA HAS ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF NOVEMBER 13, 2018
* THERAVANCE BIOPHARMA - FDA INDICATED IT DOES NOT CURRENTLY PLAN TO CONVENE AN ADVISORY COMMITTEE MEETING TO DISCUSS NDA FOR REVEFENACIN (TD-4208) Source text for Eikon: Further company coverage: